Bellevue Group Ag Recursion Pharmaceuticals, Inc. Transaction History

Bellevue Group Ag

$4.67 Billion
Q3 2025

A detailed history of Bellevue Group Ag transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 5,514 shares of RXRX stock, worth $22,827. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,514

Previous 5,514 -0.0%

Holding current value

$22,827

Previous $27,000 3.7%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$3.97 - $5.84 $752,465 - $1.11 Million	-189,538 Reduced 97.17%	5,514 $27,000
Q1 2025 May 14, 2025	SELL	$5.29 - $10.87 $966,768 - $1.99 Million	-182,754 Reduced 48.37%	195,052 $1.03 Million
Q4 2024 Feb 14, 2025	SELL	$5.7 - $8.27 $85,927 - $124,670	-15,075 Reduced 3.84%	377,806 $2.55 Million
Q3 2024 Nov 14, 2024	SELL	$5.92 - $8.6 $194,939 - $283,189	-32,929 Reduced 7.73%	392,881 $2.59 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $4,123 - $5,638	561 Added 0.13%	425,810 $3.19 Million

Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $2.29 Million - $3.89 Million	250,692 Added 143.62%	425,249 $4.24 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $2,402 - $5,092	472 Added 0.27%	174,557 $1.72 Million
Q3 2023 Nov 14, 2023	BUY	$6.59 - $15.86 $1.15 Million - $2.76 Million	174,085 New	174,085 $1.33 Million
Q3 2021 Nov 12, 2021	SELL	$19.03 - $41.33 $380,600 - $826,600	-20,000 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$18.0 - $37.42 $360,000 - $748,400	20,000 New	20,000 $730,000

Others Institutions Holding RXRX

# of Institutions

361

Shares Held

301M

Call Options Held

7.71M

Put Options Held

4.85M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $747M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Recursion Pharmaceuticals, Inc. Transaction History